VWA
ATNM icon

V Wealth Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

V Wealth Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,833
Closed -$56K – 229
2018
Q2 		$56K Buy
+2,833
New +$35.9K 0.03% 199

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

V Wealth Advisors's ATNM Position: Q3 2018 in Review

V Wealth Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2018, closing a stake of 2,833 shares — an estimated $56K sold.

V Wealth Advisors first reported a position in ATNM in Q2 2018 and held it in 1 quarter. The position peaked at $56K in Q2 2018. 42 funds tracked by Wall St. Rank hold ATNM as of Q3 2018.

  • V Wealth Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • V Wealth Advisors sold 2,833 Actinium Pharmaceuticals shares in Q3 2018, an estimated $56K.
  • V Wealth Advisors first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • V Wealth Advisors's Actinium Pharmaceuticals position peaked at $56K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2018.

Based on V Wealth Advisors's 13F filing for Q3 2018, filed 31 Oct 2018.